Everolimus + Vinorelbine + Trastuzumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER-2 Positive Breast Cancer
Conditions
HER-2 Positive Breast Cancer
Trial Timeline
Sep 1, 2011 → Oct 16, 2017
NCT ID
NCT01305941About Everolimus + Vinorelbine + Trastuzumab
Everolimus + Vinorelbine + Trastuzumab is a phase 2 stage product being developed by Novartis for HER-2 Positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01305941. Target conditions include HER-2 Positive Breast Cancer.
What happened to similar drugs?
0 of 2 similar drugs in HER-2 Positive Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01305941 | Phase 2 | Completed |
Competing Products
11 competing products in HER-2 Positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab + Capecitabine + Cisplatin | Celltrion | Phase 2 | 31 |
| eribulin + carboplatin + trastuzumab | Eisai | Phase 1/2 | 24 |
| Apatinib and S-1 | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| V930 | Merck | Phase 1 | 29 |
| IV LBH589 + Oral LBH589 + trastuzumab + paclitaxel | Novartis | Phase 1 | 29 |
| T-DM1 | Roche | Phase 2 | 35 |
| Trastuzumab + Paclitaxel + Epirubicin + Carboplatin | Roche | Phase 2 | 31 |
| palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + Fulvestrant | Pfizer | Phase 3 | 44 |
| Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab | United Therapeutics | Phase 1/2 | 36 |
| Alisertib + Endocrine therapy | Puma Biotechnology | Phase 2 | 32 |
| Margetuximab + Trastuzumab + Physician's choice of chemotherapy. | MacroGenics | Phase 3 | 30 |